美国43家医疗中心重要病原体的耐药性及胃肠外氟喹诺酮类药物的抗菌活性 - Suppr

Suppr

超能文献

Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres.

作者信息

Jones R N, Kehrberg E N, Erwin M E

机构信息

Department of Pathology, University of Iowa College of Medicine, Iowa City, USA.

出版信息

Drugs. 1995;49 Suppl 2:179-81. doi: 10.2165/00003495-199500492-00033.

DOI:10.2165/00003495-199500492-00033

PMID:8549295

Abstract

摘要

相似文献

Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres.美国43家医疗中心重要病原体的耐药性及胃肠外氟喹诺酮类药物的抗菌活性

Drugs. 1995;49 Suppl 2:179-81. doi: 10.2165/00003495-199500492-00033.

Fluoroquinolone resistance: mechanisms and epidemiology.氟喹诺酮耐药性：机制与流行病学

J Med Microbiol. 1997 Jun;46(6):457-61.

Emergence of resistance to fluoroquinolones among bacteria causing infections in food animals in Denmark.

Vet Rec. 2000 Jan 15;146(3):76-8. doi: 10.1136/vr.146.3.76.

In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone.

Drugs. 1995;49 Suppl 2:205-7. doi: 10.2165/00003495-199500492-00043.

Epidemiology of quinolone resistance: Europe and North and South America.喹诺酮耐药性的流行病学：欧洲及南北美洲

Drugs. 1995;49 Suppl 2:36-42. doi: 10.2165/00003495-199500492-00007.

In-vitro activity of E-4695, a new fluoronaphthyridine antimicrobial agent.新型氟萘啶抗菌剂E-4695的体外活性

J Antimicrob Chemother. 1994 May;33(5):1017-23. doi: 10.1093/jac/33.5.1017.

[Tosufloxacin tosilate].[妥舒沙星甲苯磺酸盐]

Jpn J Antibiot. 1990 Apr;43(4):583-602.

Changes in susceptibility to ciprofloxacin in a community in northern Israel.

Drugs. 1995;49 Suppl 2:173-4. doi: 10.2165/00003495-199500492-00030.

Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.近期临床分离株对替马沙星（A-63004）及其他抗菌药物的敏感性。

Drugs Exp Clin Res. 1992;18(8):311-7.

In vitro and in vivo antibacterial activities of CFC-222, a novel broad spectrum fluoroquinolone.

Drugs. 1995;49 Suppl 2:240-2. doi: 10.2165/00003495-199500492-00055.

引用本文的文献

Quinolones: which generation for which microbe?喹诺酮类药物：针对哪种微生物该用哪一代？

West J Med. 1999 Jun;170(6):359-61.

In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.氟罗沙星对从医院感染患者中分离出的多重耐药革兰氏阴性杆菌的体外活性。

Intensive Care Med. 1998 Aug;24(8):839-44. doi: 10.1007/s001340050675.

本文引用的文献

The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.一项国际比较性最低抑菌浓度（MIC）试验中对氧氟沙星耐药性监测的北美部分（美国和加拿大）。

Diagn Microbiol Infect Dis. 1993 Aug-Sep;17(2):157-61. doi: 10.1016/0732-8893(93)90027-5.

Inactivation of antibiotics and the dissemination of resistance genes.抗生素的失活与耐药基因的传播。

Science. 1994 Apr 15;264(5157):375-82. doi: 10.1126/science.8153624.

Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop.多重耐药病原菌。洛克菲勒大学研讨会报告。

N Engl J Med. 1994 Apr 28;330(17):1247-51. doi: 10.1056/NEJM199404283301725.

North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.北美（美国和加拿大）两种氟喹诺酮类药物（氧氟沙星和环丙沙星）的敏感性比较。53个医学中心的活性谱样本。北美氧氟沙星研究组。

Diagn Microbiol Infect Dis. 1994 Jan;18(1):49-56. doi: 10.1016/0732-8893(94)90133-3.

Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.

Diagn Microbiol Infect Dis. 1992 Jul;15(5):425-34. doi: 10.1016/0732-8893(92)90084-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验